Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has approved another indication for its product Daxxify (daxibotulinumtoxin, RT002). The type A botulinum toxin is now approved for the treatment of adult cervical muscle tone disorders in China.
Background on Daxxify (RT002) and Its Development
Daxxify, a long-acting neuromodulator originally developed by US firm Revance Therapeutics, Inc., was licensed to Fosun for commercialization in mainland China, Hong Kong, and Macau in December 2018. The product has been approved for temporary improvement of moderate to severe eyebrow wrinkles caused by the activity of the frown and/or brow muscles in adults. In the United States, Daxxify received approval for treating cervical muscle tone disorders in adults in August 2023, following its earlier approval for eyebrow wrinkles in September 2022.
Recent Approval and Implications for Fosun Pharmaceutical
The recent approval in China for cervical muscle tone disorders expands the product’s application and strengthens Fosun Pharmaceutical’s portfolio in the neuromodulator market. This approval follows the successful wave-through of the same indication in the United States in September this year, highlighting the global relevance and potential of Daxxify in addressing muscle tone disorders.-Fineline Info & Tech
